Program
cabozantinib
Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.
Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.
Drug pageCabozantinib: every studyMany companies study it; this page follows only the 33 they lead. All 223 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixisits history only | 237 open or running | phase 4since Jul 8, 2013 | Sep 20, 2005 | May 31, 2030phase 3 · NCT07620574 |
| Bristol-Myers Squibbits history only | 51 open or running | phase 3since May 3, 2017 | Nov 24, 2009 | Aug 25, 2029phase 2 · NCT03899155 |
| Ipsenits history only | 20 open or running | phase 2since May 9, 2019 | May 9, 2019 | none ahead |
| Takeda | 20 open or running | phase 2since Nov 8, 2017 | Nov 8, 2017 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Apr 23, 2018 | Apr 23, 2018 | none ahead |
Also a collaborator on its studies: Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Roche-Genentech and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 8, 2017First study: phase 2 study in Advanced Renal Cell CarcinomaFirst studyNCT03339219 · 35 enrolled · Japan
- Jun 29, 2018Phase 2 study in Advanced Hepatocellular CarcinomaNCT03586973 · 34 enrolled · Japan
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 17 |
Studies
All 2 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03586973Advanced Hepatocellular Carcinoma · Japan | 2 | Completed | Jul 17, 2019 | 34 |
| NCT03339219Advanced Renal Cell Carcinoma · Japan | 2 | Completed | Aug 25, 2020 | 35 |
How it is read
Names in the registry
- “Cabozantinib”, 18 entries
- “cabozantinib”, 9 entries
- “XL184”, 6 entries
- “Cabozantinib tablets”, 2 entries
- “Cabozantinib (XL184) 140 mg”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 6 studies
- Carcinoma, Renal Cell, 5 studies
- Prostatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 4 studies
- Glioblastoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.